FY26 revenue rises to Rs. 4,359 crore as India’s leading CDMO strengthens global footprint with EU GMP certifications, UK MHRA approval and Europe supplies
The accrued data from the Phase 3 study suggest that the baseline characteristics of the enrolled patients are consistent with those observed in previous studies
The company highlighted a series of strategic moves during the year, including the acquisition of WOKADINE, marking its entry into the Rs. 648 Cr Povidone Iodine market
The biosimilars business generated Rs. 10,431 crore in FY26 revenue, up 16% year-on-year
The investment will upgrade and expand production capabilities at Lilly Lebanon API and Lilly Lebanon Advanced Therapies
The company informed stock exchanges that the appellate authority has set aside the GST demand along with applicable interest and penalty
Compared to a net loss of Rs 12 crore in FY25, the pharma major reported a consolidated turnaround in its financial performance
In Q4 FY26, the company reported revenue from operations of Rs 176.9 crore, marking a 23.6% year-on-year growth
The company doses first patient in US study of Deraphan, as Dolby Ventures joins €53M Series B to support neuropsychiatric innovation
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
